4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioVie Inc. (BIVI) operates in the Biotechnology industry and is headquartered in Carson City, United States with about 13 employees. Its market capitalization is roughly $12 million. In the fiscal year ended 2025-06-30, BIVI reported $0M in revenue and ($18M) in net income.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
Interactive charts & full statements →
| Income statement | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($18M) | ($32M) | ($45M) | ($27M) |
| Net Income | ($18M) | ($32M) | ($50M) | ($26M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($5M) | ($6M) | ($5M) | ($4M) | ($3M) | — |
| Net Income | ($5M) | ($6M) | ($5M) | ($4M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Assets | $22M | $25M | $35M | $20M |
| Total Liabilities | $3M | $10M | $20M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIVI viewer.
About TickerBase · Data methodology & sources